Serum IL-6, sAXL, and YKL-40 as systemic correlates of reduced brain structure and function in Alzheimer’s disease: results from the DELCODE study
Authors: Brosseron Frederic , Maass Anne , Kleineidam Luca , Ravichandran Kishore Aravind , Kolbe Carl-Christian , Wolfsgruber Steffen , Santarelli Francesco , Häsler Lisa M. , McManus Róisín , Ising Christina , Röske Sandra , Peters Oliver , Cosma Nicoleta-Carmen , Schneider Luisa-Sophie , Wang Xiao , Priller Josef , Spruth Eike J. , Altenstein Slawek , Schneider Anja , Fliessbach Klaus , Wiltfang Jens , Schott Björn H. , Buerger Katharina , Janowitz Daniel , Dichgans Martin , Perneczky Robert , Rauchmann Boris-Stephan , Teipel Stefan , Kilimann Ingo , Görß Doreen , Laske Christoph , Munk Matthias H. , Düzel Emrah , Yakupow Renat , Dobisch Laura , Metzger Coraline D. , Glanz Wenzel , Ewers Michael , Dechent Peter , Haynes John Dylan , Scheffler Klaus , Roy Nina , Rostamzadeh Ayda , Spottke Annika , Ramirez Alfredo , Mengel David , Synofzik Matthis , Jucker Mathias , Latz Eicke , Jessen Frank , Wagner Michael , Heneka Michael T. ,   the DELCODE study group
Published: January 2023

Background

Neuroinflammation constitutes a pathological hallmark of Alzheimer’s disease (AD). Still, it remains unresolved if peripheral inflammatory markers can be utilized for research purposes similar to blood-based beta-amyloid and neurodegeneration measures. We investigated experimental inflammation markers in serum and analyzed interrelations towards AD pathology features in a cohort with a focus on at-risk stages of AD.

Methods

Data of 74 healthy controls (HC), 99 subjective cognitive decline (SCD), 75 mild cognitive impairment (MCI), 23 AD relatives, and 38 AD subjects were obtained from the DELCODE cohort. A panel of 20 serum biomarkers was determined using immunoassays. Analyses were adjusted for age, sex, APOE status, and body mass index and included correlations between serum and CSF marker levels and AD biomarker levels. Group-wise comparisons were based on screening diagnosis and routine AD biomarker-based schematics. Structural imaging data were combined into composite scores representing Braak stage regions and related to serum biomarker levels. The Preclinical Alzheimer’s Cognitive Composite (PACC5) score was used to test for associations between the biomarkers and cognitive performance.

Results

Each experimental marker displayed an individual profile of interrelations to AD biomarkers, imaging, or cognition features. Serum-soluble AXL (sAXL), IL-6, and YKL-40 showed the most striking associations. Soluble AXL was significantly elevated in AD subjects with pathological CSF beta-amyloid/tau profile and negatively related to structural imaging and cognitive function. Serum IL-6 was negatively correlated to structural measures of Braak regions, without associations to corresponding IL-6 CSF levels or other AD features. Serum YKL-40 correlated most consistently to CSF AD biomarker profiles and showed the strongest negative relations to structure, but none to cognitive outcomes.

Conclusions

Serum sAXL, IL-6, and YKL-40 relate to different AD features, including the degree of neuropathology and cognitive functioning. This may suggest that peripheral blood signatures correspond to specific stages of the disease. As serum markers did not reflect the corresponding CSF protein levels, our data highlight the need to interpret serum inflammatory markers depending on the respective protein’s specific biology and cellular origin. These marker-specific differences will have to be considered to further define and interpret blood-based inflammatory profiles for AD research.